BioProtect is an Israel-based medtech startup that is working on a spacer balloon that helps radiotherapy and oncological procedures. Now, the startup raised a $13M Series D. One of the investors is the single family office of Vincent Tchenguiz.Innovative technology against rectal toxicityBioProtect initially developed a technology to produce biodegradable balloons – which can be used in various clinical applications. One main use case of BioProtect’s spacer balloon is the protection of healthy tissue for patients who receive prostate radiotherapy. BioProtect’s balloons are made of bioresorbable polymer. Through the biodegradable design, the balloon disappears within six months. Thereby, there is no need for additional surgical procedures. BioProtect is led by CEO Gil Rosen and Co-Founder and CTO Shaul Shohat. Shohat already had two successful exits in the medtech space.$13M Series D Equity Financing from various investorsIn total, BioProtect raised $13M with its recent Series D. Investors include the Korean firm KB Investments, VC Accelmed Ventures II and the . Tchenguiz is an Iranian-British entrepreneur who has an estimated net worth of 850M GBP. The Tchenguiz family mainly earnt their wealth through the establishment of the Rotch Property Group. The family office is an active investor in European (and especially Israeli) tech firms. He was the largest shareholder of Cambridge Analytica and one of the investors in defense technology startup eViglio.SourcesYou might also like these family office articlesRelevant Family Office Lists Rated 4.00 out of 5 €399,99 including VAT €4,99 including VAT Rated 4.67 out of 5 €499,99 including VAT Rated 4.67 out of 5 €1.499,99 including VAT
User Comments1. E.
Johnson: Comment sample 1...2. Young,
Ethan: Comment sample 2...3. Layla
Carter: Comment sample 3...4. Ethan W.: Comment sample 4...5. Brown,
Sebastian: Comment sample 5...Editor's NoteThis article was refined for clarity, structure, and user experience.
(Editors: admin)
Disclaimer & Copyright Notice:
This article is edited and compiled by the editorial team at WealthShield Asia based on publicly available information. It is intended for informational purposes only and does not constitute legal, financial, or investment advice.
We respect intellectual property rights. If you believe that any part of this article infringes upon your copyright or other legal rights, please contact us at
admin@wealthshield.asia. We will promptly review and remove the content if necessary.
All rights reserved. Unauthorized reproduction or redistribution is prohibited.
